LifeStance Health Group, Inc. (LFST) Form 8-K — Nov 4, 2026
LifeStance Health delivered a standout Q3 2026, with revenue up 25% year-over-year to $455.9 million and net income of $22.4 million versus just $1.1 million a year ago. Adjusted EBITDA surged 70% to $68.4 million on strong operating leverage, with the margin expanding to 15.0% of revenue. Growth was driven by an 11% larger clinician base (8,863 clinicians, +321 net adds in the quarter) and 17% higher visit volumes, alongside improving revenue per visit of $169.70. The company ended Q3 with $218.8 million in cash against $255.5 million net long-term debt.
Key figures
- Eps
- 0.06
- Revenue
- 455900000
- Guidance
- FY2026 revenue raised to $1.741B-$1.761B, Center Margin to $599M-$613M, Adjusted EBITDA to $242M-$250M; Q4 2026 revenue $446M-$466M, Center Margin $149M-$163M, Adjusted EBITDA $56M-$64M
- Net Income
- 22400000
- Total Debt
- 255500000
- Revenue Yoy
- 25%
- Total Assets
- 2186000000
- Cash Position
- 218800000
- Clinicians
- 8863
- Visit volume
- 2.7 million (+17% Y/Y)
- Center margin
- $161.4 million (+38% Y/Y, 35.4% of revenue)
- Adjusted ebitda
- $68.4 million (+70% Y/Y, 15.0% of revenue)
- Q3 free cash flow
- $22.4 million
- Clinician growth yoy
- 11%
- Share repurchases ytd
- $122.4 million
- Operating cash flow ytd
- $170.0 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.